Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm

American Journal of Clinical Pathology

Volumn 137, Issue 6, 2012, Pages 937-945

  Wang, Fengmei ^a   Jing, Xiang ^b   Wang, Tao ^b   Li, Ge ^c   Li, Tinghong ^b   Zhang, Qin ^b   Huang, Yong ^a   Li, Jun ^b   Wang, Yijun ^b   Gao, Yingtang ^d   Han, Tao ^b   Du, Zhi ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b THIRD CENTRAL HOSPITAL OF TIANJIN   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Tianjin Key Laboratory of Artificial Cell   (China)

Author keywords

CD34; Diagnosis; Glypican 3; Hepatocellular carcinoma

Indexed keywords

CD34 ANTIGEN; GLYPICAN 3; GLYPICAN; TUMOR MARKER;

ADULT; ARTICLE; BIOPSY TECHNIQUE; CANCER DIAGNOSIS; CIRRHOTIC REGENERATIVE NODULE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HIGH GRADE DYSPLASTIC NODULE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THIN CORE BIOPSY; TUMOR VOLUME; AGED; LIVER; LIVER CIRRHOSIS; LIVER TUMOR; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIGENS, CD34; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GLYPICANS; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863735365     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP0KZZ5DSIGMNY     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
3. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59:638-644.
4. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol. 2010;105:599-609.
5. Park YN, Kojiro M, Di Tommaso L, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer. 2007;109:915-923. (Pubitemid 46333533)
6. Nam SW, Park JY, Ramasamy A, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology. 2005;42:809-818. (Pubitemid 41401118)
7. Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 2007;45:938-947. (Pubitemid 46646500)
8. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108:497-501. (Pubitemid 32777726)
9. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725-734. (Pubitemid 46450624)
10. Baumhoer D, Tornillo L, Stadlmann S, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008;129:899-906.
11. Di Tommaso L, Destro A, Seok JY, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009;50:746-754.
12. Tangkijvanich P, Chanmee T, Komtong S, et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol. 2010;25:129-137.
13. Di Tommaso L, Destro A, Fabbris V, et al. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology. 2011;53:1549-1557.
14. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
15. de Boer WB, Segal A, Frost FA, et al. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies? Cancer. 2000;90:273-278.
16. Tátrai P, Somoracz A, Batmunkh E, et al. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol. 2009;33:874-885.
17. Ding T, Xu J, Zhang Y, et al. Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection [published online ahead of print April 8, 2011]. Cancer. 2011;117:4878-4889. doi:10.1002/cncr.26137.
18. Coston WM, Loera S, Lau SK, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol. 2008;32:433-444. (Pubitemid 351398936)
19. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61-74.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. (Pubitemid 43112690)
21. Hirohashi S, Ishak KG, Kojiro M, et al. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000:159-172.
22. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology. 2009;49:658-664.
23. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111:316-322.
24. Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953-962.